Drug Profile
VBY 891
Alternative Names: VBY-891Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Virobay
- Class Antipsoriatics; Small molecules
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain; Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Psoriasis in USA (PO, Capsule)
- 18 Mar 2013 Phase-I clinical trials in Psoriasis in USA (PO)
- 21 Apr 2012 No development reported - Preclinical for Neuropathic pain in USA (PO)